Table 5.
IRR of each neuropsychiatric outcome comparing the mefloquine cohort to the atovaquone/proguanil cohort by deployment status
| Outcome | Deployed | Nondeployed | ||
|---|---|---|---|---|
| Unadjusted IRR (95% CI) | Adjusted IRR* (95% CI) | Unadjusted IRR (95% CI) | Adjusted IRR* (95% CI) | |
| Adjustment disorder | 0.91 (0.73–1.13) | 1.01 (0.74–1.37) | 1.38 (1.13–1.69) | 1.31 (0.99–1.74) |
| Insomnia | 0.68 (0.54–0.86) | 0.80 (0.58–1.10) | 0.94 (0.74–1.19) | 1.07 (0.78–1.48) |
| Anxiety disorder | 0.97 (0.71–1.33) | 0.97 (0.64–1.48) | 1.07 (0.82–1.39) | 0.98 (0.67–1.43) |
| Tinnitus | 1.31 (0.93–1.86) | 1.81 (1.18–2.79) | 1.24 (1.00–1.54) | 1.51 (1.13–2.03) |
| Depressive disorder | 1.76 (1.12–2.75) | 1.56 (0.89–2.74) | 1.25 (0.94–1.67) | 1.36 (0.90–2.04) |
| Vertigo | 1.27 (0.51–3.14) | 1.24 (0.34–4.54) | 0.83 (0.43–1.61) | 1.04 (0.43–2.49) |
| Posttraumatic stress disorder | 1.65 (1.04–2.61) | 1.31 (0.75–2.29) | 1.32 (0.90–1.94) | 1.83 (1.07–3.14) |
| Suicide ideation | 2.90 (0.71–11.82) | 3.56 (0.45–28.40) | 1.04 (0.54–1.98) | 1.00 (0.36–2.79) |
| Convulsions | 0.44 (0.21–0.95) | 0.39 (0.14–1.12) | 2.46 (1.15–5.27) | 1.72 (0.60–4.92) |
| Psychosis | – | – | 2.64 (0.53–13.10) | 7.18 (1.00–51.65) |
| Hallucinations | 0.18 (0.03–0.97) | 0.09 (0.01–1.20) | 0.18 (0.02–1.52) | 0.43 (0.02–8.40) |
| Paranoia | – | – | – | – |
| Suicide | – | – | 0.88 (0.06–14.09) | 2.59 (0.03–225.47) |
| Confusion | – | – | – | – |
CI = confidence interval; IRR = incidence rate ratio.
*
Models adjusted for age, sex, service, grade, year of prescription start; deployed model also adjusted for location and combat exposure.